Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile®
Viruses · 2024
DOI: 10.3390/v16040510 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, 2024. Verfasst von Daisy Ko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Genotyping Techniques, Receptors, CCR5, Receptors, CXCR4. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
HIV-1 typically infects cells via the CD4 receptor and CCR5 or CXCR4 co-receptors. Maraviroc is a CCR5-specific viral entry inhibitor; knowledge of viral co-receptor specificity is important prior to usage. We developed and validated an economical V3-env Illumina-based assay to detect and quantify the frequency of viruses utilizing each co-receptor. Plasma from 54 HIV+ participants (subtype B) was tested. The viral template cDNA was generated from plasma RNA with unique molecular identifiers (UMIs). The sequences were aligned and collapsed by the UMIs with a custom bioinformatics pipeline. Co-receptor usage, determined by codon analysis and online phenotype predictors PSSM and Geno2pheno, were compared to existing Trofile® data. The cost of V3-UMI was tallied. The sequences interpreted by Geno2pheno using the most conservative cut-off, a 2% false-positive-rate (FPR), predicted CXCR4 usage with the greatest sensitivity (76%) and specificity (100%); PSSM and codon analysis had similar sensitivity and lower specificity. Discordant Trofile® and genotypic results were more common when participants had specimens from different dates analyzed by either assay. V3-UMI reagents cost USD$62/specimen. A batch of ≤20 specimens required 5 h of technical time across 1.5 days. V3-UMI predicts HIV tropism at a sensitivity and specificity similar to those of Trofile®, is relatively inexpensive, and could be performed by most central laboratories. The adoption of V3-UMI could expand HIV drug therapeutic options in lower-resource settings that currently do not have access to phenotypic HIV tropism testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
- Department of Microbiology, University of Washington, Seattle, WA 98195, USA.
- Department of Medicine, University of Washington, Seattle, WA 98104, USA.
- Department of Global Health, University of Washington, Seattle, WA 98105, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
- Department of Pediatrics, University of Washington, Seattle, WA 98195, USA.
ORCID-Profile: Socorro Harb, Lisa M Frenkel
Förderung
- NICHD NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Ko, D., McLaughlin, S., Deng, W., Mullins, J. I., Dragavon, J., Harb, S., Coombs, R. W., & Frenkel, L. M. (2024). Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile®. Viruses. https://doi.org/10.3390/v16040510
Vancouver
Ko D, McLaughlin S, Deng W, Mullins JI, Dragavon J, Harb S, et al. Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile®. Viruses. 2024. doi:10.3390/v16040510
BibTeX
@article{Ko2024,
author = {Ko, Daisy and McLaughlin, Sherry and Deng, Wenjie and Mullins, James I and Dragavon, Joan and Harb, Socorro and Coombs, Robert W and Frenkel, Lisa M},
title = {Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile®},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16040510}
}
EUVIMED